AGILENT TECHNOLOGIES, INC. (A) FY2026 Q3 P&L / Income Statement

Revenue by Business Segment by Geography

2026-05-01 to 2026-07-31

Swipe to see the full flow
AGILENT TECHNOLOGIES, INC. (A) FY2026 Q3 P&L / Income StatementIncome statement for 2026-05-01 through 2026-07-31. View: Segments by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories.SOURCESREVENUEGROSSOPERATINGPRE-TAXNETLife Sciences and Diagnostics Markets - AmericasAgilent CrossLab - AmericasAgilent CrossLab - Asia PacificAgilent CrossLab - EuropeLife Sciences and Diagnostics Markets - EuropeLife Sciences and Diagnostics Markets - Asia PacificApplied Markets - Asia PacificApplied Markets - AmericasApplied Markets - EuropeNet revenueGross profit (calculated)Total cost of revenue (calculated)Cost of revenueIncome from operationsOperating expenses (calculated)Selling, general and administrativeResearch and developmentIncome before taxesNet incomeProvision for income taxesGross profit (calculated)Gross profit(calculated)$1.04 BNet revenueNet revenue$1.88 BIncome from operationsIncome from operations$444.00 MIncome before taxesIncome before taxes$444.00 MLife Sciences and Diagnostics Markets - AmericasLife Sciences and DiagnosticsMarkets - Americas$369.00 MNet incomeNet income$362.00 MAgilent CrossLab - AmericasAgilent CrossLab - Americas$289.00 MOperating expenses (calculated)Operating expenses(calculated)$598.00 MProvision for income taxesProvision forincome taxes$82.00 MAgilent CrossLab - Asia PacificAgilent CrossLab - Asia Pacific$276.00 MSelling, general and administrativeSelling, general and administrative$475.00 MTotal cost of revenue (calculated)Total cost of revenue(calculated)$836.00 MAgilent CrossLab - EuropeAgilent CrossLab - Europe$221.00 MResearch and developmentResearch and development$123.00 MLife Sciences and Diagnostics Markets - EuropeLife Sciences andDiagnostics Markets - Europe$201.00 MLife Sciences and Diagnostics Markets - Asia PacificLife Sciences and DiagnosticsMarkets - Asia Pacific$176.00 MCost of revenueCost of revenue$836.00 MApplied Markets - Asia PacificApplied Markets - Asia Pacific$161.00 MApplied Markets - AmericasApplied Markets - Americas$103.00 MApplied Markets - EuropeApplied Markets - Europe$82.00 M
Chart details

AGILENT TECHNOLOGIES, INC. (A) FY2026 Q3 P&L / Income Statement

Income statement for 2026-05-01 through 2026-07-31. View: Segments by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Net revenue
1,878,000,000 US dollars
Total cost of revenue (calculated)
836,000,000 US dollars
Gross profit (calculated)
1,042,000,000 US dollars
Operating expenses (calculated)
598,000,000 US dollars
Income from operations
444,000,000 US dollars
Other income (expense), net (calculated)
0 US dollars
Income before taxes
444,000,000 US dollars
Provision for income taxes
82,000,000 US dollars
Net income
362,000,000 US dollars
Agilent CrossLab - Americas
289,000,000 US dollars
Agilent CrossLab - Asia Pacific
276,000,000 US dollars
Agilent CrossLab - Europe
221,000,000 US dollars
Applied Markets - Americas
103,000,000 US dollars
Applied Markets - Asia Pacific
161,000,000 US dollars
Applied Markets - Europe
82,000,000 US dollars
Life Sciences and Diagnostics Markets - Americas
369,000,000 US dollars
Life Sciences and Diagnostics Markets - Asia Pacific
176,000,000 US dollars
Life Sciences and Diagnostics Markets - Europe
201,000,000 US dollars
Cost of revenue
836,000,000 US dollars
Research and development
123,000,000 US dollars
Selling, general and administrative
475,000,000 US dollars

Chart connections

  • Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
  • Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
AGILENT TECHNOLOGIES, INC. (A) FY2026 Q3 Revenue by Business Segment by Geography Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Gross margin

55.5%

Gross profit / revenue

Operating margin

23.6%

Operating profit / revenue

Cash conversion

143.4%

Operating cash / net income, same period

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!